The study involved 1,246 smokers who wanted to quit.
“Our data suggests treating normal metabolisers with varenicline and slow metabolisers with the nicotine patch,” co-lead author Rachel Tyndale, from the University of Toronto, in Canada, added.
“What is more, it is feasible that a point-of-care blood test to measure the rate at which nicotine is metabolised could be developed and implemented in clinical practice,” Tyndale said.
- Delhi election Feb 7, result Feb 10
- Kerosene Dealers Up in Arms Again on New Kerosene Quota